Evidence map›Paper›PMID 29276377›Full record

ReviewBiologics : targets & therapy2017

Anti-angiogenic effects of biotechnological therapies in rheumatic diseases.

Francesco Paolo Cantatore, Nicola Maruotti, Addolorata Corrado, Domenico Ribatti

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biologics : targets & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Francesco Paolo CantatoreRheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia.
Nicola MaruottiRheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia.
Addolorata CorradoRheumatology Clinic, Department of Medical and Surgical Sciences, University of Foggia Medical School, Foggia.
Domenico RibattiDepartment of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School.
University of Foggia · ITIstituto Tumori Bari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAngiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases.

methodsThis review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. RESULTS AND

conclusionsSeveral evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. Nevertheless, further research and clinical trials are needed to better quantify the real impact of biotechnological therapies on pathological angiogenesis.

Indexed as

abataceptanakinraangiogenesisrituximabTNF-αtocilizumab

Identifiers

PMID29276377
PMCPMC5733924
OpenAlexW2775220646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.